8.00

1.36% -0.11

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $8.00, with a volume of 1.51M. It is down -1.36% in the last 24 hours and up +5.12% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Previous Close:

$8.11

Open:

$8.11

24h Volume:

1.51M

Relative Volume:

1.15

Market Cap:

$1.12B

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-15.09

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

-2.56%

1M Performance:

+5.12%

6M Performance:

-3.85%

1Y Performance:

+54.74%

1-Day Range:

$7.93

$8.21

1-Week Range:

$7.885

$8.34

52-Week Range:

$4.99

$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	8.00	1.12B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

May 09, 2025

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st

May 09, 2025

May 06, 2025

How the (AUPH) price action is used to our Advantage - news.stocktradersdaily.com

May 06, 2025

May 05, 2025

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - BioSpace

May 05, 2025

Apr 30, 2025

Glass Lewis Supports Aurinia’s Proposals for 2025 AGM - TipRanks

Apr 30, 2025

ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting - TipRanks

Apr 30, 2025

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire

Apr 30, 2025

Apr 29, 2025

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - BioSpace

Apr 29, 2025

Aurinia Pharmaceuticals (AUPH) Gains Support from ISS for Board - GuruFocus

Apr 29, 2025

Apr 26, 2025

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (NASDAQ:AUPH) - Seeking Alpha

Apr 26, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025

Apr 23, 2025

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire

Apr 23, 2025

Apr 19, 2025

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN

Apr 19, 2025

Apr 17, 2025

Aurinia Sues Galenicum to Block Copies of Lupkynis Kidney Drug - Bloomberg Law News

Apr 17, 2025

Apr 11, 2025

Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement - Law360

Apr 11, 2025

Apr 07, 2025

High Growth Tech Stocks To Watch In The US Market - simplywall.st

Apr 07, 2025

Apr 02, 2025

Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)? - Yahoo

Apr 02, 2025

Apr 01, 2025

Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st

Apr 01, 2025

Mar 25, 2025